Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient
Provided is an antimalarial drug which is useful for prevention and treatment of infectious diseases caused by malaria parasites. A preventive and/or therapeutic agent for malaria, which contains, as an active ingredient, 5-aminolevulinic acid (ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is used.
1. A method for treating or preventing malaria in a subject without performing light irradiation comprising the steps of:
identifying a subject suspected of having malaria; and
administering a therapeutically effective amount of a compound represented by the following formula (I) or a pharmacologically acceptable salt thereof,
wherein R 1 represents a hydrogen atom or an acyl group, and R 2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aralkyl group, or an aryl group; in combination with one or more kinds of metal-containing compounds, wherein the metal portion of the metal-containing compound is iron, magnesium, or zinc.
2. The method of claim 1 , comprising administering a therapeutically effective amount of the compound represented by formula (I) or a pharmacologically acceptable salt thereof in combination with one or more kinds of metal-containing compounds, wherein the metal portion of the metal-containing compound is iron, magnesium, or zinc, and further in combination with one or more kinds of known antimalarial drugs.
3. The method of claim 1 , comprising administering a therapeutically effective amount of the compound represented by formula (I) or a pharmacologically acceptable salt thereof in combination with one or more kinds of metal-containing compounds, wherein the metal portion of the metal-containing compound is iron, magnesium, or zinc to an antimalarial drug-resistant patient.
4. The method of claim 2 , comprising administering a therapeutically effective amount of the compound represented by formula (I) or a pharmacologically acceptable salt thereof in combination with one or more kinds of metal-containing compounds, wherein the metal portion of the metal-containing compound is iron, magnesium, or zinc and further in combination with one or more kinds of known antimalarial drugs to an antimalarial drug-resistant patient.
5. The method of claim 1 , wherein R 1 and R 2 each represent a hydrogen atom.
6. The method of claim 1 , comprising administering a therapeutically effective amount of the compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein R 1 and R 2 each represent a hydrogen atom, in combination with one or more kinds of metal-containing compounds, wherein the metal portion of the metal-containing compound is iron, magnesium, or zinc, and further in combination with one or more kinds of known antimalarial drugs.
7. The method of claim 1 , comprising administering a therapeutically effective amount of the compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein R 1 and R 2 each represent a hydrogen atom, in combination with one or more kinds of metal-containing compounds, wherein the metal portion of the metal-containing compound is iron, magnesium, or zinc to an antimalarial drug-resistant patient.